SCHEMBL2090388

SCHEMBL2090388

COc1cc(NC(=O)OC(C)(C)C)cc(OC)c1OC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 7/20 0.54
▸ HTT P42858 1/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ CYP2C19 P33261 1/20 0.44
▸ PDE4A P27815 2/20 0.44
▸ PDE4C Q08493 2/20 0.44
▸ PDE4D Q08499 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ GRIN2B Q13224 1/20 0.43
▸ ENPP2 Q13822 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ YAP1 P46937 1/20 0.42
▸ LNPEP Q9UIQ6 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26655327 0.85 ALDH1A1 (0.54) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL13198829 0.84 SMN1; SMN2 (0.50) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL2951356 0.84 LNPEP (0.48) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL4040675 0.82 SMN1; SMN2 (0.56) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL2087849 0.82 SMN1; SMN2 (0.58) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL12781649 0.79 PDE4B (0.47) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL12845381 0.79 PDE4B (0.46) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL304546 0.77 SMN1; SMN2 (0.58) PDE4BHTTSMN1; SMN2NPC1RAB9A
SCHEMBL5235275 0.77 BCHE (0.50) SMN1; SMN2NPC1RAB9ACYP2C9ALDH1A1
SCHEMBL282296 0.77 ALDH1A1 (0.48) PDE4BHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 — — EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed
EP-1562589-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-17 — — EP disclosed
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-28 — — US disclosed
WO-2004046120-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 PDE4B 635/4885HTT 2381/4885SMN1; SMN2 3129/4885
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K5 PDE4B 635/4885HTT 2381/4885SMN1; SMN2 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback